Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule

Patent metadata

Field	Value
Publication number	US-12186304-B2
Application number	US-201916618792-A
Country	US
Kind code	B2
Filing date	Jul 30, 2019
Priority date	Jul 31, 2018
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure pertains to the field of biomedicine, and specifically relates to a method for treating, suppressing, reducing the severity of, lowering the risk of, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and optionally a therapeutically effective amount of a tubulin inhibitor. The present disclosure further relates to a pharmaceutical composition or kit comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and optionally a tubulin inhibitor.

First claim

The invention claimed is:

1. A method for treating cancer, suppressing_cancer, reducing the severity of cancer, lowering the risk of cancer, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor, a therapeutically effective amount of a modulator of an immune checkpoint molecule, and a therapeutically effective amount of a tubulin inhibitor;
wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is anti-PD-1 antibody, and the tubulin inhibitor is docetaxel or paclitaxel.

2. The method of claim 1 , wherein the modulator of an immune checkpoint molecule is selected from the group consisting of pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, durvalumab, AGEN-1884, BMS-986016, CS1001, CS-1002, LAG525, MBG453, MEDI-570, OREG-103/BY40, lirilumab, tremelimumab, JS001, SHR-1210, BGB-A317, IBI-308, REGN2810, JS003, SHR-1316, KN035 and BMS-936559.

3. The method of claim 1 , wherein the cancer is selected from the group consisting of adrenocortical cancer, anal cancer, cholangiocarcinoma, bladder cancer, bone cancer, bone metastasis cancer, adult brain/central nervous system tumor, childhood brain/central nervous system tumor, breast cancer, male breast cancer, childhood cancer, Castleman disease, Merkel cell carcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma family tumor, eye cancer, gallbladder cancer, digestive tract cancer, gastrointestinal stromal tumor (GIST), trophoblastic cancer, head and neck cancer, Kaposi's sarcoma, renal cancer, renal cell cancer, laryngeal and hypopharyngeal cancer, leukemia, liver cancer, lung cancer, lymphoma, cutaneous lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal and nasalsinus cancer, nasopharyngeal cancer, neuroblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, childhood non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, malignant pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, skin cancer, small intestinal cancer, testicular cancer, thymic cancer, thyroid cancer, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor, urothelial cancer, microsatellite instability solid tumor and choriocarcinoma.

4. The method of claim 1 , wherein the IAP inhibitor is administered in an amount of about 0.005 mg/day to about 5000 mg/day.

5. The method of claim 1 , wherein the modulator of an immune checkpoint molecule or the tubulin inhibitor is administered in an amount of about 0.005 mg/week to about 5000 mg/week.

6. The method of claim 1 , wherein the IAP inhibitor, modulator of an immune checkpoint molecule, and tubulin inhibitor are administered together, concurrently, sequentially or alternately.

7. The method of claim 1 , wherein the IAP inhibitor, modulator of an immune checkpoint molecule or tubulin inhibitor is administered for one or more courses of treatment, wherein each course of treatment lasts for at least 3 days; wherein for each course of treatment, administration is performed 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times; and the interval between every two courses of treatment is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 days, two weeks, three weeks, four weeks, one month or two months.

8. The method of claim 1 , wherein the individual suffers from a refractory cancer, a recurrent cancer or a resistant cancer that is resistant to a cancer therapy comprising the modulator of an immune checkpoint molecule and/or the tubulin inhibitor.

9. A pharmaceutical composition comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, a tubulin inhibitor, and a pharmaceutically acceptable carrier;
wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is anti-PD-1 antibody, and the tubulin inhibitor is docetaxel or paclitaxel.

10. A kit comprising:
(a) a first component in a first container, the first component comprising an IAP inhibitor;
(b) a second component in a second container, the second component comprising a modulator of an immune checkpoint molecule; and
(c) a third component in a third container, the third component comprising a tubulin inhibitor;
wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is anti-PD-1 antibody, and the tubulin inhibitor is docetaxel or paclitaxel.

11. A method for treating cancer, suppressing cancer, reducing the severity of cancer, lowering the risk of cancer, or inhibiting the metastasis of cancer in an individual, the method comprising administering to the individual a therapeutically effective amount of an IAP inhibitor and a therapeutically effective amount of a modulator of an immune checkpoint molecule;
wherein the IAP inhibitor is APG-1387 and the modulator of an immune checkpoint molecule is anti-PD-1 antibody; and
wherein the cancer is selected from the group consisting of colon cancer, colorectal cancer, ovarian cancer, lymphoma, nasopharyngeal cancer and liver cancer.

12. A pharmaceutical composition for use in the treatment of cancer comprising an IAP inhibitor, a modulator of an immune checkpoint molecule, and a pharmaceutically acceptable carrier;
wherein
the IAP inhibitor is APG-1387 and the modulator of an immune checkpoint molecule is anti-PD-1 antibody; the cancer is selected from the group consisting of colon cancer, colorectal cancer, ovarian cancer, lymphoma, nasopharyngeal cancer and liver cancer.

13. The method of claim 1 , wherein the method comprises at least one 21-day treatment cycle, wherein the IAP inhibitor is administrated on days 1, 8 and 15 of the consecutive 3-weeks of the treatment cycle.

14. The method of claim 13 , wherein APG-1387 is administered via an intravenous infusion.

15. The method of claim 13 , wherein the therapeutically effective amount is from about 15 mg to about 100 mg, or is from 20 to 45 mg, or from 20 mg to 60 mg of IAP inhibitor.

16. The method of claim 13 , wherein the therapeutically effective amount is 20 mg, 30 mg, 45 mg, 60 mg or 80 mg.

17. The method of claim 13 , wherein the cancer is metastatic pancreatic cancer, colorectal cancer, ovarian cancer, lymphoma, or liver cancer.

18. The method of claim 13 , wherein the method further comprises administering a therapeutically effective amount of carboplatin.

19. The method of claim 11 , wherein and the modulator of an immune checkpoint molecule is pembrolizumab, and wherein APG-1387 is administered with pembrolizumab for treating a patient suffering from advanced solid tumors or hematologic malignancies.

20. The method of claim 13 , wherein the IAP inhibitor is APG-1387, the modulator of an immune checkpoint molecule is pembrolizumab, and further comprising administration of docetaxel, and wherein APG-1387 is administered with pembrolizumab and docetaxel for treating a patient suffering from advanced solid tumors or hematologic malignancies.

21. The method of claim 3 , wherein the cancer is head and neck cancer, microsatellite instability solid tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, non-small cell lung cancer, renal cell cancer, bladder cancer, melanoma, squamous cell carcinoma, Merkel cell tumor, urothelial cancer, nasopharyngeal cancer and colorectal cancer.

22. The method of claim 17 , wherein the cancer is hepatocellular carcinoma.

Assignees

• Ascentage Pharma Suzhou Co Ltd

Inventors

• Yang Dajun
• Zhai Yifan
• Fang Douglas Dong
• Wang Guangfeng
• Tang Qiuqiong
• Pan Wentao
• Ji jiao

Classifications

• A61K31/5517

  condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title

• C07K16/2818

  against CD28 or CD152 · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title